Home  »  Trending   »  We Analyzed the Future Direction of Protalix BioTh...

We Analyzed the Future Direction of Protalix BioTherapeutics Inc. (PLX), Here is What We Found

Protalix BioTherapeutics Inc. (AMEX:PLX) went down by -17.37% from its latest closing price compared to the recent 1-year high of $2.00. The company’s stock price has collected -14.81% of loss in the last five trading sessions.

Is It Worth Investing in Protalix BioTherapeutics Inc. (AMEX :PLX) Right Now?

Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Protalix BioTherapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


The average price from analysts is $11.00. PLX currently public float of 41.64M and currently shorts hold a 4.35% ratio of that float. Today, the average trading volume of PLX was 385.63K shares.

PLX’s Market Performance

PLX stocks went down by -14.81% for the week, with a monthly jump of 6.15% and a quarterly performance of 34.06%, while its annual performance rate touched 65.61%. The volatility ratio for the week stands at 7.81% while the volatility levels for the past 30 days are set at 5.79% for Protalix BioTherapeutics Inc. The simple moving average for the period of the last 20 days is -5.09% for PLX stocks with a simple moving average of 19.87% for the last 200 days.

Analysts’ Opinion of PLX

Many brokerage firms have already submitted their reports for PLX stocks, with H.C. Wainwright repeating the rating for PLX by listing it as a “Buy.” The predicted price for PLX in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on June 08th of the previous year 2020.

Rodman & Renshaw, on the other hand, stated in their research note that they expect to see PLX reach a price target of $5, previously predicting the price at $4. The rating they have provided for PLX stocks is “Buy” according to the report published on April 17th, 2017.

Rodman & Renshaw gave a rating of “Buy” to PLX, setting the target price at $3.50 in the report published on April 04th of the previous year.

PLX Trading at 10.07% from the 50-Day Moving Average

After a stumble in the market that brought PLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.00% of loss for the given period.

Volatility was left at 5.79%, however, over the last 30 days, the volatility rate increased by 7.81%, as shares surge +7.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +35.29% upper at present.

During the last 5 trading sessions, PLX fell by -14.81%, which changed the moving average for the period of 200-days by -6.12% in comparison to the 20-day moving average, which settled at $1.4590. In addition, Protalix BioTherapeutics Inc. saw 0.73% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at PLX starting from Schwartz Aharon, who purchase 110,000 shares at the price of $1.42 back on Jan 03. After this action, Schwartz Aharon now owns 174,000 shares of Protalix BioTherapeutics Inc., valued at $155,815 using the latest closing price.

Bashan Dror, the President and CEO of Protalix BioTherapeutics Inc., purchase 68,000 shares at $1.50 during a trade that took place back on Apr 11, which means that Bashan Dror is holding 68,000 shares at $102,000 based on the most recent closing price.

Stock Fundamentals for PLX

Current profitability levels for the company are sitting at:

  • -53.36 for the present operating margin
  • +57.37 for the gross margin

The net margin for Protalix BioTherapeutics Inc. stands at -71.92.

The liquidity ratio also appears to be rather interesting for investors as it stands at 1.86.

Is SSR Mining Inc. (SSRM) a Keeper?

SSR Mining Inc. (NASDAQ:SSRM) went down by -3.03% from its latest closing price compared to the recent 1-year high of $24.58. The company’s stock price